TNXP

Tonix is a pre-profit specialty pharma whose entire equity value rests on one just-launched product. TONMYA (sublingual cyclobenzaprine for fibromyalgia) was FDA-approved in August 2025 and only went on sale November 17, 2025 — so FY2025's $13.1M of revenue (up 29.8%) reflects legacy migraine products (Zembrace, Tosymra), not the launch. Against that trickle of revenue the company lost $124M and burned $99.8M in operating cash, for an operating margin of -959%. Management's own 10-K carries an auditor going-concern paragraph and states plainly it 'will need additional capital to fund our operations' and that 'our prospects are highly dependent on the success of TONMYA.' That is the definition of unknowable, binary risk.

The balance sheet looks superficially clean — $208M cash, only $32M total liabilities, liabilities/equity of 0.13x — but that cash was bought with brutal dilution: shares outstanding rose 108.3% in a single year, and the $-14.57 diluted EPS on just 13.4M shares is the fingerprint of a reverse split layered on top of relentless issuance. With a ~$100M annual burn, $208M funds roughly two years before the next raise, and a commercial ramp typically raises, not lowers, cash consumption — consistent with the going-concern flag. The accumulated deficit of -$855M shows this has never worked as a business. Spending $13.8M on buybacks while burning $100M and flagging going concern is a curious, value-questionable use of scarce cash.